Lecanemab Unveiled: Exploring Alzheimer's Treatment Advancements, Assessing Strengths, Limitations, and Its Therapeutic Landscape Position
Biomed Environ Sci
.
2024 Apr 20;37(4):428-431.
doi: 10.3967/bes2024.047.
Authors
Victor Abiola Adepoju
1
,
Okechukwu Innocent Onyezue
2
,
Safayet Jamil
3
,
Olalekan John Okesanya
4
,
Eliseo Lucero-Prisno Iii Don
5
Affiliations
1
Department of HIV and Infectious Diseases, Jhpiego, an affiliate of John Hopkins University, Abuja, Nigeria.
2
Department of Prevention and Community Directorate, APIN Public Health Initiatives, Abuja, Nigeria.
3
Department of Public Health, Daffodil International University, Dhaka-1216, Bangladesh.
4
Department of Public Health and Maritime Transport, University of Thessaly, Volos, Greece.
5
Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom.
PMID:
38727166
DOI:
10.3967/bes2024.047
No abstract available
Publication types
Letter
MeSH terms
Alzheimer Disease* / drug therapy
Alzheimer Disease* / therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Substances
Antibodies, Monoclonal, Humanized